Altered Expression of Tissue Inhibitor of Matrix Metalloproteinase-2 in Complicated Mice Heart Secondary to Experimentally Induced Viral Myocarditis.
- Author:
Sung Sook KIM
1
;
Dae Woon EOM
;
Yeong Ju WOO
;
Jae Hee SUH
;
Jooryung HUH
;
Young Me HONG
;
Inpyo CHOI
Author Information
1. Department of Pathology, School of Medicine, Ulsan University, Ulsan 682-060, Korea, sskim@uuh.ulsan.kr
- Publication Type:Original Article
- Keywords:
Myocarditis;
Cardiomyopathy;
Gelatinase B;
Tissue inhibitor of matrix metalloproteinase-2;
Immunohistochemistry
- MeSH:
Animals;
Cardiomyopathies;
Cardiomyopathy, Dilated;
Connective Tissue;
Heart*;
Herpesvirus 1, Cercopithecine;
Humans;
Immunoassay;
Immunoblotting;
Immunohistochemistry;
Incidence;
Matrix Metalloproteinase 2*;
Matrix Metalloproteinase 9;
Mice*;
Myocarditis*;
Myocardium;
Myocytes, Cardiac;
Tissue Inhibitor of Metalloproteinase-2
- From:Korean Journal of Pathology
2001;35(3):196-200
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The pathogenesis of transition from viral myocarditis to dilated cardiomyopathy is elusive, although the incidence of dilated cardiomyopathy in human is increasing. METHODS: To clarify the role of the tissue inhibitor of matrix metaloproteinase-2 (TIMP-2) in this event, we performed immunohistochemistry, immunoblotting and immunoassay of matrix metalloproteinase-9 (MMP-9) and TIMP-2 in the serum and heart tissue of mice, which were inoculated with 4000 plaque-forming units of coxsackie B virus. RESULTS: The MMP-9 was expressed in damaged cardiomyocytes, and the TIMP-2 was expressed in mainly interstitial connective tissue between cardiac muscle bundles by immunohistochemistry. The level of serum MMP-9 was higher in the complicated than non-complicated group (p<0.001), but the level of TIMP-2 was much lower in complicated than non-complicated group (p<0.05). These findings were similar to the results of immunohistochemistry and immunoblotting in tissues. CONCLUSIONS: These results suggest that an imbalance in the level of MMP-9 and its inhibitor might activate cardiac complication in viral myocarditis.
